套细胞淋巴瘤18例的预后相关因素分析  

Prognostic factors of mantle cell lymphomas：analysis of18 cases

作　　者：丁晓蕾[1] 张磊[1] 张弦[1] 徐丽叶[1] 孙秀华[1] 

机构地区：[1]大连医科大学附属第二医院肿瘤四科,大连116027

出　　处：《中华老年多器官疾病杂志》2015年第11期825-828,共4页Chinese Journal of Multiple Organ Diseases in the Elderly

摘　　要：目的：通过分析套细胞淋巴瘤（MCL）的临床特征，探讨影响预后的相关因素，指导临床实践。方法收集2008年7月至2014年7月收治的18例MCL患者的临床资料，回顾性地分析性别、年龄、套细胞淋巴瘤国际预后指数（MIPI）评分、骨髓受侵情况、美国东部肿瘤协作组（ECOG）评分、B症状、Ki-67水平、乳酸脱氢酶（LDH）、白细胞（WBC）、淋巴细胞（LYM）、临床分期、首次治疗方法等各因素，采用Fisher精确检验对累积生存率进行比较，生存资料及预后分析采用乘积极限法（Kaplan-Meier法）绘制生存曲线。多因素分析采用Cox比例风险模型分析各临床要素对疾病预后的影响。结果年龄＜65岁与≥65岁分组（P＝0.036）、MIPI评分低危、中危、高危分组（P＝0.049）、ki-67＜30%或≥30%（P＝0.001）与预后具有相关性，而性别、B症状、ECOG评分、β2微球蛋白、LDH、WBC、LYM、临床分期、首次治疗方法统计后差异无统计学意义（P＞0.05）。结论患者的年龄＜65岁预后好。MIPI评分中、低危组预后好，高危组预后差。免疫表型中Ki-67＜30%较≥30%的患者预后好。ObjectiveTo investigate the clinical features of mantle cell lymphoma（MCL）and the prognostic factors in order to guide the clinical practice.Methods Clinical data of 18 patients withMCLadmitted in our hospitalfrom July 2008 to July 2014 were collected and retrospectively analyzedin this study. Theirsex,age,B symptoms, invasion of bone marrow,scores ofMantle Cell LymphomaInternational Prognostic Index （MIPI）,Eastern Cooperative Oncology Group （ECOG） scores, serumlevels of Ki-67 and lactate dehydrogenase（LDH）,white blood cell （WBC） and lymphocyte（LYM） counts, clinical stages, initialtherapy andclinical outcomes were analyzed.Fisher exact testwas used to compare thecumulative survival. Kaplan-Meiersurvival analysis was employedto draw survival curve. The prognostic factors were analyzed by Cox proportional hazard model.ResultsAge （younger or older than 65 years,P=0.036）, MIPI scores （low-, medium- and high-risk,P=0.049） andKi-67 level（〈30% and≥30%, P=0.001） were correlated withprognosis, but sex, ECOG scores, B symptoms,β2-microglubulin,LDH level, WBC count, LYM count, clinical stages andinitialtherapywere not （P〉0.05）.ConclusionYounger than 65 years,low ormediumMIPI scores and Ki-67 below 30%are favorable prognostic factors forMCL.

关 键 词：套细胞淋巴瘤 临床特征 预后 

分 类 号：R733.4[医药卫生—肿瘤]